Tauriga Sciences Inc. Generates Record Weekly Net E-Commerce Sales
Tauriga Sciences Inc. Generates Record Weekly Net E-Commerce Sales
For the Following Weekly Period: November 22nd-28th, 2021 or Thanksgiving Week 2021
以下每週：2021年11月22日至28日或2021年感恩節周
NEW YORK, NY, Nov. 29, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Tauriga Sciences, Inc. (OTCQB: TAUG) ("Tauriga" or the "Company"), a New York based diversified Life Sciences Company, today announced that it has generated record weekly net E-Commerce revenue ("sales"), for the following period: Monday November 22, 2021 through Sunday November 28, 2021. The Company's net E-Commerce sales, for this one-week period, have exceeded $22,000 for the first time. The Company is confident about its business prospects for the remainder of Calendar Year 2021 and beyond.
紐約，紐約，2021年11月29日(環球通訊社)--通過NewMediaWire--總部設在紐約的多元化生命科學公司Tauriga Sciences，Inc.(OTCQB：TAUG)(以下簡稱“Tauriga”或“公司”)今天宣佈，該公司在2021年11月22日(星期一)至2021年11月28日(星期日)期間創造了創紀錄的每週電子商務淨收入(“銷售額”)。在這一週的時間裏，該公司的電子商務淨銷售額首次超過2.2萬美元。該公司對2021年日曆年剩餘時間及以後的業務前景充滿信心。
Throughout its current operating Quarter (3rd Fiscal Quarter 2022), the Company has experienced an acceleration in revenue growth – concerning its highest margin E-Commerce business segment. Driving this revenue growth are several important factors: innovative product offerings, increased orders from repeat customers, and aggressive new marketing strategies.
整個當前運營季度(3研發2022財季)，該公司經歷了收入增長的加速-涉及其利潤率最高的電子商務業務部門。推動這一收入增長的是幾個重要因素：創新的產品供應、來自回頭客的訂單增加，以及積極的新營銷戰略。
The Company is firmly on track to generate record quarterly revenue (net revenue), for its 3rd Fiscal Quarter 2022. The Company expects that net revenue generated for this quarter, when completed, will be substantially greater than any other previous quarter.
該公司堅定地走在創造創紀錄的季度收入(淨收入)的軌道上，研發2022財季。該公司預計，完成後，本季度產生的淨收入將大大超過以往任何一個季度。
Please visit the Company's recently upgraded E-Commerce website, at:
請訪問公司最近升級的電子商務網站，網址為：
Lastly, the Company wishes to congratulate Aegea Biotechnololgies, Inc. ("Aegea") on the completed clinical validation for its new COVID-19 Assay ("Test"). Tauriga Sciences, Inc. currently holds a meaningful equity stake in Aegea.
最後，本公司祝賀Aegea生物技術公司(“Aegea”)完成了其新的新冠肺炎檢測(“檢測”)的臨牀驗證。Tauriga Sciences，Inc.目前持有Aegea的大量股權。
** Please Note: 3rd Fiscal Quarter 2022 (Period: October 1, 2021 – December 31, 2021)
**請注意：3研發2022財季(期間：2021年10月1日-2021年12月31日)
ABOUT TAURIGA SCIENCES INC.
關於Tauriga Science Inc.
Tauriga Sciences, Inc. (TAUG) is a revenue generating, diversified life sciences company, engaged in several major business activities and initiatives. The company manufactures and distributes several proprietary retail products and product lines, mainly focused on the Cannabidiol ("CBD") and Cannabigerol ("CBG") Edibles market segment. The main product line, branded as Tauri-Gum™, consists of a proprietary supplement chewing gum that is Kosher certified, Halal certified, and Vegan Formulated (CBD Infused Tauri-Gum™ Flavors: Mint, Blood Orange, Pomegranate), (CBG Infused Tauri-Gum™ Flavors: Peach-Lemon, Black Currant), (DELTA 8 THC Infused Tauri-Gum™ Flavor: Evergreen Mint), (Vitamin C + Zinc Infused Tauri-Gum™ Flavor: Pear Bellini), (Caffeine Infused Tauri-Gum™ Flavor: Cherry Lime Rickey), & (Vitamin D3 Infused Tauri-Gum™ Flavor: Golden Raspberry). The Company's commercialization strategy consists of a broad array of retail customers, distributors, and a fast-growing E-Commerce business segment (E-Commerce website: www.taurigum.com). Please visit our corporate website, for additional information, as well as inquiries, at
Tauriga Sciences，Inc.(TAUG)是一家創收的多元化生命科學公司，從事幾項主要的商業活動和計劃。該公司製造和分銷多個專有零售產品和產品線，主要集中在大麻二醇(“CBD”)和大麻酚(“CBG”)食用細分市場。主要產品線，品牌為金牛膠™，由一個專有的補充劑口香糖，這是猶太認證，清真認證，素食配方(CBD注入金牛膠™口味：薄荷，血橙，石榴)，(CBG注入金牛膠™口味：桃子檸檬，黑加侖)，(臺達8THC注入金牛膠™口味：常綠薄荷)，(該公司的商業化戰略包括廣泛的零售客户、分銷商和快速增長的電子商務業務部門(電子商務網站：www.taurigum.com)。如需更多信息和查詢，請訪問我們的公司網站，網址為
Complementary to the Company's retail business, is its ongoing Pharmaceutical Development initiative. This relates to the development of a proposed Pharmaceutical grade version of Tauri-Gum™, for nausea regulation (specifically designed for the following indication: Patients Subjected to Ongoing Chemotherapy Treatment). On March 22, 2021, the Company announced that it had Converted its U.S. Provisional Patent Application (filed on March 17, 2020) into a U.S. Non-Provisional Patent Application. The Patent, filed with the U.S.P.T.O. is Titled "MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT". On December 18, 2020 the Company disclosed that it had entered into a Master Services Agreement with CSTI to lead the Company's clinical development efforts.
與該公司零售業務相輔相成的是其正在進行的藥品開發計劃。這涉及到開發一種建議的藥學級版本的Tauri-Gum™，用於調節噁心(專門為以下適應症設計：正在接受化療的患者)。2021年3月22日，該公司宣佈已將其美國臨時專利申請(於2020年3月17日提交)轉換為美國非臨時專利申請。向美國專利商標局提交的這項專利的標題是“藥物CBD組合物、製造方法和治療方法”。2020年12月18日，該公司披露，它已經與CSTI簽訂了一項主服務協議，以領導公司的臨牀開發工作。
The Company is headquartered in Wappingers Falls, New York. In addition, the Company operates two full time E-Commerce fulfillment centers: one located in Montgomery, Texas and the other in Brooklyn, New York.
該公司總部設在紐約州瓦平格斯福爾斯。此外，該公司還運營着兩個全職電子商務履行中心：一個位於德克薩斯州的蒙哥馬利，另一個位於紐約的布魯克林。
DISCLAIMER -- Forward-Looking Statements
免責聲明--前瞻性聲明
This press release contains certain "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995 which represent management's beliefs and assumptions concerning future events. These forward-looking statements are often indicated by using words such as "may," "will," "expects," "anticipates," believes, "hopes," "believes," or plans, and may include statements regarding corporate objectives as well as the attainment of certain corporate goals and milestones. Forward-looking statements are based on present circumstances and on management's present beliefs with respect to events that have not occurred, that may not occur, or that may occur with different consequences or timing than those now assumed or anticipated. Actual results may differ materially from those expressed in forward looking statements due to known and unknown risks and uncertainties, such as are not guarantees of general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to consummate successful acquisition and licensing transactions, fluctuations in exchange rates, and other factors over which Tauriga has little or no control. Many of these risks and uncertainties are discussed in greater detail in the "Risk Factors" section of Tauriga's Form 10-K and other periodic filings made from time to time with the Securities and Exchange Commission. Such forward-looking statements are made only as of the date of this release, and Tauriga assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. You should not place undue reliance on these forward-looking statements.
本新聞稿包含1995年“私人證券訴訟改革法”所界定的某些“前瞻性陳述”，這些陳述代表管理層對未來事件的信念和假設。這些前瞻性陳述通常使用諸如“可能”、“將會”、“預期”、“預期”、“相信”、“希望”、“相信”或“計劃”等詞語來表示，可能包括有關公司目標以及某些公司目標和里程碑的實現情況的陳述。前瞻性陳述基於當前情況以及管理層目前對尚未發生、可能發生或可能發生的事件的信念，這些事件的後果或時機與現在假設或預期的不同。由於已知和未知的風險和不確定性，實際結果可能與前瞻性陳述中表述的大不相同，例如不能保證一般的經濟和商業條件，成功開發和銷售產品的能力，消費者和企業的消費習慣，完成成功的收購和許可交易的能力，匯率的波動，以及Tauriga幾乎或無法控制的其他因素。其中許多風險和不確定性在Tauriga公司的10-K表格和其他不定期提交給證券交易委員會的文件中的“風險因素”部分有更詳細的討論。此類前瞻性陳述僅在本新聞稿發佈之日作出，Tauriga不承擔更新前瞻性陳述以反映後續事件或情況的義務。您不應該過分依賴這些前瞻性陳述。
Contact:
聯繫方式：
Tauriga Sciences, Inc.
Tauriga Sciences，Inc.
4 Nancy Court, Suite 4
南希苑4號套房
Wappingers Falls, NY 12590
紐約州瓦平格斯福爾斯，郵編：12590
Chief Executive Officer
首席執行官
Mr. Seth M. Shaw
Seth M.Shaw先生
Email: sshaw@tauriga.com
電子郵件：sshaw@tauriga.com
cell # (917) 796 9926
電話號碼：(917)7969926
Company Instagram: @taurigum
公司Instagram：@taurigum
Personal Instagram: @sethsms47
個人Instagram：@sethsms47
Twitter: @SethMShaw
推特：@SethMShaw
Corp. Website: www.tauriga.com
公司網站：www.tauriga.com
E-Commerce Website: www.taurigum.com
電子商務網站：www.taurigum.com
譯文內容由第三人軟體翻譯。